BioSpace News Archive

RELIEF THERAPEUTICS Holding SA, a Swiss, commercial-stage biopharmaceutical company identifying, developing and commercializing novel, patent protected products in selected specialty, rare and ultra-rare disease areas on a global basis, announced that Paolo Galfetti has been promoted to Chief Operating Officer, effective October 14, 2022.

4Moving Biotech, a biotechnology company and subsidiary of 4P-Pharma, focusing on the development of a first-in-class disease modifying osteoarthritis drug for a curative treatment of osteoarthritis, announces that it has enrolled its first patient for phase I of LASARE clinical trial study.

MedMira Inc. announces the receipt of the CE mark for its VYRA™ COVID-19 Antigen Test, the fastest SARS-CoV-2 Antigen test available.

Matchpoint Therapeutics, a biotechnology company founded to leverage the power of covalency for the discovery of precision small molecule medicines, launched with $100 million in financing.

BeiGene announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion recommending approval of BRUKINSA® for the treatment of adult patients with chronic lymphocytic leukemia.

Myovant Sciences, announced it will host a webcast and conference call to discuss corporate updates and financial results for its second fiscal quarter, ended September 30, 2022.

Phanes Therapeutics, Inc. announced that it has received clearance from the US Food and Drug Administration to commence Phase I studies with PT217, its anti-Delta-like ligand 3 /anti-Cluster of differentiation 47 bispecific antibody being developed for patients with small cell lung cancer and other neuroendocrine cancers.

NanoViricides, Inc., reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2022 with the Securities and Exchange Commission on Thursday, October 13, 2022.

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that four posters will be presented at the upcoming American Society of Nephrology’s (ASN) Kidney Week 2022 Annual Meeting.

Galectin Therapeutics Inc., the leading developer of therapeutics that target galectin proteins, announced the Company will be presenting at two upcoming conferences.